Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts
June 16 2016 - 8:30AM
Business Wire
Pfizer Inc. today broke ground for its new biologics clinical
manufacturing facility in Andover, Massachusetts. Expanding the
company’s presence in the state, Pfizer will invest more than $200
million in development of the 175,000 sq. ft. state-of-the-art
facility that will enable the production of high-quality, complex
biologics and vaccines. The new 5-story building is expected to be
operational by January 2019. Approximately 75 new employees will be
hired to support clinical manufacturing. In addition to the Andover
campus, Massachusetts is home to Pfizer’s Research and Development
hub in Cambridge. Pfizer has approximately 2,000 employees based in
Massachusetts.
Pfizer’s Andover campus currently includes 7 buildings which
house laboratories, clinical and commercial manufacturing suites,
and support areas. It also includes a multiproduct manufacturing
facility, which allows clinical and commercial products to be
manufactured simultaneously, supporting a range of Pfizer product
supply.
The new clinical manufacturing facility is designed with 5
independent manufacturing suites to support Pfizer’s highly complex
and diverse biologics research effort. The facility will:
- Employ flexible design to fully enable
Next Generation Manufacturing strategies
- Leverage state-of-the-art single-use
bioreactors and disposable process technologies
- Provide clinical manufacturing options
with the lowest cost and greatest flexibility for efficiently
driving important clinical drugs to patients
“The expansion of Pfizer’s presence in Andover will provide
state-of-the-art manufacturing to help bring new medicines and
vaccines to the patients we serve,” said John Ludwig, senior vice
president, BioTherapeutics Pharmaceutical Sciences in Pfizer
R&D. “Andover is a crucial part of our global footprint for
both clinical and commercial manufacturing, and we believe it
provides an attractive location for growth in the coming
years.”
"Pfizer's decision to expand their campus in Andover speaks to
the Commonwealth's continued global leadership in biopharma and our
administration's support of the growing advanced manufacturing
sector," said Lieutenant Governor Karyn Polito. "We are pleased to
have Pfizer operating in Andover, Boston and Cambridge and look
forward to their ongoing contributions to the Massachusetts's
economy and wellbeing of our citizens.”
“This five-story building will add 75 new permanent
manufacturing jobs and 200 temporary construction jobs to Pfizer’s
Andover campus, already home to 1,200 employees,” Senator Barbara
L’Italien said. “This project is a testament to Pfizer’s commitment
to Andover and I look forward to the facility opening in early
2019.”
Pfizer Inc.: Working together for a healthier
world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of healthcare
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer healthcare
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. For more information, please visit us at
www.pfizer.com. In addition, to learn more, follow us on Twitter at
@Pfizer and @Pfizer_news, LinkedIn,YouTube, and like us on
Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of June 16, 2016. Pfizer assumes no obligation to
update forward-looking statements contained in this release as the
result of new information or future events or developments. This
release contains forward-looking information about Pfizer’s new
biologics clinical manufacturing facility in Andover,
Massachusetts, including its potential benefits and the anticipated
timing of completion, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, risks related to the
ability to realize the anticipated benefits of the new facility and
the ability to complete construction in the anticipated timeframe
or at all; other business effects, including the effects of
industry, market, economic, political or regulatory conditions; and
competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616005626/en/
Pfizer Media:Dean Mastrojohn,
917-580-2423Dean.Mastrojohn@Pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024